Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

POOJA GHATALIA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1336406461
CMS profile
4760629
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$9,576.36

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $9,537.00 1
Food and Beverage $39.36 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $9,556.69 2
Eisai Inc. $19.67 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

POOJA GHATALIA

NPI 1336406461 · CMS profile ID 4760629

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336406461?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
POOJA GHATALIA, NPI 1336406461, CMS profile ID 4760629. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336406461?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). POOJA GHATALIA, NPI 1336406461, CMS profile ID 4760629. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336406461?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
POOJA GHATALIA, NPI 1336406461, CMS profile ID 4760629, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1336406461?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $9,576.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $9,537.0010/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048821941 CMS
Merck Sharp & Dohme LLC $19.6909/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048833277 CMS
Eisai Inc. $19.6702/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023327433 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2023 $9,576.36 3
PY2025 $26.82 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,478,341.14 9
PY2024 Principal investigator $1,536,981.08 11
PY2023 Principal investigator $1,205,727.16 11
PY2022 Principal investigator $1,134,059.16 14
PY2021 Principal investigator $1,894,818.35 9
PY2020 Principal investigator $902,348.25 132
PY2019 Principal investigator $111,378.10 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

132 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $87,316.94 12/31/2020 Non-covered Recipient Entity
The Institute For Cancer Research
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 736739601
Principal investigator 1 Merck Sharp & Dohme Corporation $17,300.00 12/16/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 740743125
Principal investigator 1 Merck Sharp & Dohme Corporation $2,000.00 12/16/2020 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 740779943
Principal investigator 1 Merck Sharp & Dohme Corporation $745.80 12/14/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 740703219
Principal investigator 1 Merck Sharp & Dohme Corporation $38,893.50 12/14/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775877
Principal investigator 1 Merck Sharp & Dohme Corporation $22,208.00 12/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775875
Principal investigator 1 Merck Sharp & Dohme Corporation $191.75 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 740703215
Principal investigator 1 Merck Sharp & Dohme Corporation $94.32 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775189
Principal investigator 1 Merck Sharp & Dohme Corporation $2.94 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775593
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775635
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775637
Principal investigator 1 Merck Sharp & Dohme Corporation $3.60 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775639
Principal investigator 1 Merck Sharp & Dohme Corporation $47.25 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775641
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775643
Principal investigator 1 Merck Sharp & Dohme Corporation $5.31 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775683
Principal investigator 1 Merck Sharp & Dohme Corporation $66.06 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775685
Principal investigator 1 Merck Sharp & Dohme Corporation $70.50 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775687
Principal investigator 1 Merck Sharp & Dohme Corporation $20.79 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775879
Principal investigator 1 Merck Sharp & Dohme Corporation $1.54 12/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775883
Principal investigator 1 Merck Sharp & Dohme Corporation $17,236.42 11/13/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775831
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775591
Principal investigator 1 Merck Sharp & Dohme Corporation $22.02 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775595
Principal investigator 1 Merck Sharp & Dohme Corporation $5.04 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775645
Principal investigator 1 Merck Sharp & Dohme Corporation $0.48 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775731
Principal investigator 1 Merck Sharp & Dohme Corporation $0.98 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775735
Principal investigator 1 Merck Sharp & Dohme Corporation $1.10 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775737
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775783
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775785
Principal investigator 1 Merck Sharp & Dohme Corporation $96.80 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775829
Principal investigator 1 Merck Sharp & Dohme Corporation $23.58 11/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775881
Principal investigator 1 Merck Sharp & Dohme Corporation $6,707.00 11/04/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775789
Principal investigator 1 Merck Sharp & Dohme Corporation $31,102.74 10/14/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775837
Principal investigator 1 Merck Sharp & Dohme Corporation $58.95 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775191
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775589
Principal investigator 1 Merck Sharp & Dohme Corporation $23.50 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775597
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775689
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775691
Principal investigator 1 Merck Sharp & Dohme Corporation $44.04 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775693
Principal investigator 1 Merck Sharp & Dohme Corporation $0.88 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775733
Principal investigator 1 Merck Sharp & Dohme Corporation $1.68 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775739
Principal investigator 1 Merck Sharp & Dohme Corporation $1.77 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775741
Principal investigator 1 Merck Sharp & Dohme Corporation $1.96 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775779
Principal investigator 1 Merck Sharp & Dohme Corporation $11.97 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775781
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 10/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775885
Principal investigator 1 Merck Sharp & Dohme Corporation $972.35 09/24/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 740703221
Principal investigator 1 Merck Sharp & Dohme Corporation $21,410.52 09/16/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775835
Principal investigator 1 Merck Sharp & Dohme Corporation $253.00 09/15/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 740743345
Principal investigator 1 Merck Sharp & Dohme Corporation $94.32 09/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775179
Principal investigator 1 Merck Sharp & Dohme Corporation $79.20 09/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775873
Principal investigator 1 Merck Sharp & Dohme Corporation $367.94 08/28/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775497
Principal investigator 1 Merck Sharp & Dohme Corporation $8,521.00 08/21/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775827
Principal investigator 1 Merck Sharp & Dohme Corporation $63,733.75 08/12/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775787
Principal investigator 1 Merck Sharp & Dohme Corporation $0.99 08/10/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775181
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 08/10/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775185
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 08/10/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775493
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 08/10/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775495
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 08/10/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775541
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 08/10/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775863
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 08/10/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775865
Principal investigator 1 Merck Sharp & Dohme Corporation $47.00 08/10/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775867
Principal investigator 1 Merck Sharp & Dohme Corporation $72.60 08/10/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775871
Principal investigator 1 Merck Sharp & Dohme Corporation $17,588.00 08/05/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775833
Principal investigator 1 Merck Sharp & Dohme Corporation $2,000.00 07/17/2020 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740779941
Principal investigator 1 Merck Sharp & Dohme Corporation $94.32 07/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775177
Principal investigator 1 Merck Sharp & Dohme Corporation $18.90 07/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775183
Principal investigator 1 Merck Sharp & Dohme Corporation $2.88 07/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775187
Principal investigator 1 Merck Sharp & Dohme Corporation $2.94 07/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775489
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 07/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775491
Principal investigator 1 Merck Sharp & Dohme Corporation $0.99 07/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775539
Principal investigator 1 Merck Sharp & Dohme Corporation $3.54 07/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775825
Principal investigator 1 Merck Sharp & Dohme Corporation $66.06 07/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775869
Principal investigator 1 Merck Sharp & Dohme Corporation $140.64 06/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775721
Principal investigator 1 Merck Sharp & Dohme Corporation $61.84 06/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775771
Principal investigator 1 Merck Sharp & Dohme Corporation $32,149.95 05/13/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775777
Principal investigator 1 Merck Sharp & Dohme Corporation $0.98 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775675
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775677
Principal investigator 1 Merck Sharp & Dohme Corporation $1.21 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775679
Principal investigator 1 Merck Sharp & Dohme Corporation $1.77 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775681
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775719
Principal investigator 1 Merck Sharp & Dohme Corporation $22.02 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775723
Principal investigator 1 Merck Sharp & Dohme Corporation $23.50 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775725
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775727
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775729
Principal investigator 1 Merck Sharp & Dohme Corporation $47.16 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775767
Principal investigator 1 Merck Sharp & Dohme Corporation $6.93 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775769
Principal investigator 1 Merck Sharp & Dohme Corporation $60.50 05/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775823
Principal investigator 1 Merck Sharp & Dohme Corporation $7,770.00 04/08/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775817
Principal investigator 1 Merck Sharp & Dohme Corporation $117.51 04/02/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775527
Principal investigator 1 Merck Sharp & Dohme Corporation $9.31 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775165
Principal investigator 1 Merck Sharp & Dohme Corporation $9.60 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775167
Principal investigator 1 Merck Sharp & Dohme Corporation $1.17 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775169
Principal investigator 1 Merck Sharp & Dohme Corporation $1.56 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775171
Principal investigator 1 Merck Sharp & Dohme Corporation $11.40 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775173
Principal investigator 1 Merck Sharp & Dohme Corporation $117.50 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775175
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775477
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775479
Principal investigator 1 Merck Sharp & Dohme Corporation $15.93 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775481
Principal investigator 1 Merck Sharp & Dohme Corporation $19.38 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775483
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775485
Principal investigator 1 Merck Sharp & Dohme Corporation $2.64 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775487
Principal investigator 1 Merck Sharp & Dohme Corporation $2.85 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775525
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775531
Principal investigator 1 Merck Sharp & Dohme Corporation $20.40 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775533
Principal investigator 1 Merck Sharp & Dohme Corporation $212.22 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775535
Principal investigator 1 Merck Sharp & Dohme Corporation $0.14 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775575
Principal investigator 1 Merck Sharp & Dohme Corporation $0.16 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775577
Principal investigator 1 Merck Sharp & Dohme Corporation $0.50 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775579
Principal investigator 1 Merck Sharp & Dohme Corporation $22.27 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775581
Principal investigator 1 Merck Sharp & Dohme Corporation $23.61 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775583
Principal investigator 1 Merck Sharp & Dohme Corporation $0.60 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775585
Principal investigator 1 Merck Sharp & Dohme Corporation $231.21 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775623
Principal investigator 1 Merck Sharp & Dohme Corporation $3.40 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775625
Principal investigator 1 Merck Sharp & Dohme Corporation $0.72 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775631
Principal investigator 1 Merck Sharp & Dohme Corporation $0.99 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775633
Principal investigator 1 Merck Sharp & Dohme Corporation $1.00 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775671
Principal investigator 1 Merck Sharp & Dohme Corporation $1.14 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775673
Principal investigator 1 Merck Sharp & Dohme Corporation $0.17 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775815
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775853
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775855
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775857
Principal investigator 1 Merck Sharp & Dohme Corporation $40.86 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775859
Principal investigator 1 Merck Sharp & Dohme Corporation $41.50 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775861
Principal investigator 1 Merck Sharp & Dohme Corporation $54.81 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775899
Principal investigator 1 Merck Sharp & Dohme Corporation $6.80 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775901
Principal investigator 1 Merck Sharp & Dohme Corporation $60.50 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775903
Principal investigator 1 Merck Sharp & Dohme Corporation $7.60 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775905
Principal investigator 1 Merck Sharp & Dohme Corporation $78.75 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775907
Principal investigator 1 Merck Sharp & Dohme Corporation $84.70 03/09/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775909
Principal investigator 1 Merck Sharp & Dohme Corporation $9,000.00 03/02/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775627
Principal investigator 1 Merck Sharp & Dohme Corporation $9,000.00 03/02/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775629
Principal investigator 1 Merck Sharp & Dohme Corporation $240.00 02/25/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 740775529
Principal investigator 1 AstraZeneca Pharmaceuticals LP $502,315.09 01/28/2020 Non-covered Recipient Entity
The Institute For Cancer Research
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer No dispute reported 06/30/2026 736743813